Skip to main content

Table 1 Association between relaxin-2 mRNA expression and clinicopathologic factors

From: Role of relaxin-2 in human primary osteosarcoma

Clinicopathologic factor Total Serum relaxin-2   Relaxin-2 mRNA expression
(mean ± SEM) (ng/mL) P-Value Low(n) High(n) P-Value
Sex    0.456    0.568
Female 20 88.24 ± 13.27   7 13  
Male 16 91.58 ± 12.36   8 8  
Age(Years)    0.087    0.092
<20 21 95.23 ± 14.16   6 15  
≥20 15 83.62 ± 12.61   9 6  
Tumor location    0.562    0.67
Extremity 14 91.54 ± 15.13   6 8  
Axial 22 89.67 ± 14.86   9 13  
Histologic subtypes    0.893    0.746
Osteoblastic 12 91.65 ± 13.02   5 7  
Chondroblastic 10 90.54 ± 13.48   4 6  
Fibroblastic 9 89.04 ± 14.23   3 6  
Telangiectactic 5 91.86 ± 13.35   3 2  
Clinical stage    0.004    0.018
I + II 20 76. 4 ± 15.27   11 9  
III 16 114.53 ± 17.26   4 12  
Hematogenous metastasis    0.001    0.002
No 15 70.53 ± 10.42   11 4  
Yes 21 108.6 ± 14.87   4 17  
Grade       0.742
High 30 89.12 ± 13.90 0.642 11 19  
Moderate 3 94.40 ± 12.16   2 1  
Low 3 96.18 ± 12.45   2 1